Home hemodialysis system maker NxStage Medical (NSDQ:NXTM) urged the Centers for Medicare & Medicaid Services to increase coverage for home hemodialysis training for patients with end-stage renal disease.
Dialysis
Baxter and Gambro seal the deal on $3.9B acquisition
Aussie regulators approve Baxter’s $4B Gambro merger
More legal trouble for Fresenius
Baxter appeases EU regulators in $4B Gambro buyout
Diabetes: Do smartphones fit the bill for the next mobile artificial pancreas? | MassDevice.com On Call
MASSDEVICE ON CALL — Smartphones are capable of meeting all the criteria for an artificial pancreas by providing close-loop, outpatient control of glucose levels for diabetics, according to a new study published by the American Diabetes Assn.
NxStage Medical pares losses and boosts sales, but still takes a hit on Wall Street
NxStage Medical (NSDQ:NXTM) beat the Street’s earnings-per-share estimate by 1 penny and reported an 11% bump in sales, but it wasn’t enough to stop shares from sliding 4% this morning.
DARPA grants $23M contract to Battelle, NxStage and Aethlon for a sepsis treatment
Baxter hits 52-week high on earnings beat
Sources say Baxter’s near an agreement with EU regulators in $4B Gambro merger
More criticism for Medicare’s dialysis cuts
The Center for Medicare & Medicaid Service’s proposal to cut about 12% from its End-Stage-Renal-Disease treatment reimbursement program drew harsh words from the non-profit Renal Support Network.
Organization CEO Lori Hartwell called the proposal "draconian" and warned that the cuts most harms patients, especially those with limited access to dialysis care.